3P Biopharmaceuticals

In July 2019, Keensight Capital, a pan-European private equity firm, acquired a majority stake from Infarco, a move designed to accelerate 3P's global growth, expand production capacity, and broaden its service offerings. This partnership marked a new phase of development for the company. A pivotal milestone occurred in February 2024 when 3P Biopharmaceuticals merged with Biovian, a Finnish CDMO founded in 2003 by Antti Nieminen and Jani Yomaa. This combination, orchestrated by their common shareholder Keensight Capital, created a new entity named 3PBIOVIAN. The merger formed a pan-European CDMO leader with over 500 employees, combined gross sales exceeding €75 million, and manufacturing facilities in Spain and Finland. The new leadership structure consists of Dámaso Molero as Group CEO and former Biovian CEO Antti Nieminen as Deputy CEO.

3PBIOVIAN operates as a CDMO, serving a global client base of biotech and pharmaceutical companies. The business model is centered on providing end-to-end services that support clients through the entire lifecycle of a drug, from preclinical development to full-scale commercial manufacturing. Revenue is generated by offering these specialized contract services. The company's service portfolio is comprehensive, covering both drug substance and drug product manufacturing. Core services include process development and GMP manufacturing for biologics and cell therapy products. The company utilizes multiple expression platforms, including microbial and mammalian systems. Following the merger with Biovian, the service offering expanded significantly to include viral vector production (adenoviruses and adeno-associated viruses), cell therapy, plasmid DNA production, and fill-and-finish services for recombinant proteins and viral vectors. This integrated service offering allows 3PBIOVIAN to manage the complexities of biopharmaceutical development and manufacturing for its international clientele.